Declaration of COI Statement – **Adjunct Associate Professor Glenn Francis**

**Research Grant Support:**

- Phenotypic/Genotypic profiling in Breast Cancer
- Study Education and Research Trust Fund $143,286 2006
- Purchase of Tissue Microarrayer Golden Casket Foundation $94,027 2006
- Prediction of lymph node status in breast cancer Study Education and Research Trust Fund $72,300.00 2007
- Slide Path Distiller software $70,000.00 Study Education and Research Trust Fund
- Novel Strategies for Prediction and Control of Advanced Breast Cancer via Nanoscaled Epigenetic-Based Biosensors NBCF $5 million 2008-2012
- Novel nanoparticle-based biosensor technology for multiplexed detection of methylation profiles in breast cancer metastases NBCF/Cancer Council $600,000 2008-2010
- Investigation of an epidemiologically proven cluster of breast cancer cases PAH Foundation $50,000 2008.
- ACRF Comprehensive Cancer genomics Facility, Associate Investigator, $3.2 million 2007
- Smart State Innovation Building Fund $2.96 million, Principal Investigator, 2008
- Smart State NIRAP Prostate Collaboration $2 million, Collaborator, 2008
- Prostate Cancer Research Centre $7.5 million, Pathologist, 2009-2013
- Capital Funding PAH Foundation $100,000, 2010.
- NGS, PAH Private Practice Trust Fund $315,000, 2011.
- Improved treatment outcomes for breast cancer patients through protein-based diagnosis with IGF family biomarkers WRI $131,300 2011-2012.

**Commercial Support:**

- No personal financial reimbursement from any pharmaceutical or biotechnology company.
- Medical Advisor
  - Roche Pharmaceutical
  - Merck Serano
  - Astra Zeneca
- Sponsorship to attend international scientific conferences from the following companies:
  Roche Pharmaceutical/Diagnostics.

- Establishment of private companies for research, Prognostic Pathology Research Facility Pty Ltd and Bioprognostics Pty Ltd.
- Provisional patent US 61/551720

**Professional Positions External to Griffith University:**

- Department of Health and Aging Genetics Working Party 2011 - current
- President Australasian Immunohistochemistry Society 2011 - current
- RCPA QAP Performance Monitoring Project Committee 2011 - current
- Pathology Queensland Workforce Plan Project Control Group 2011 - 2012
- Molecular Pathology Advisory Board 2011 - current
- EGFR IHC Expert Panel 2011 - current
- RCPA Tissue Banking Working Party 2011 - current
- Pathology Strategic Issues management Group 2011 - 2012
- MSAC Medical Expert Standing Committee 2011 - current
- Convenor Immunohistochemistry RCPA QAP 2001- current
- Committee RCPA Quality Assurance Program Breast module 2004 - current
- Chairman RCPA Quality Assurance and Scientific Education Committee 2007 – 2011
- Member RCPA Council 2007 – 2011
- Technical Reference Group, Quality Use of Pathology Program 2007 - current
- RCPA Quality Assurance and Scientific Education Committee 2004- 2011
- RCPA General Pathology Advisory Committee 2004 – current
- RCPA General Pathology Examiner 2006 – current
- RCPA curriculum development 2005 - 2006
- RCPA State Committee 2004 – current
- RCPA Board of Education Committee 2003 - 2009
- Australian Medical Association
- Royal College of Pathologists of Australasia
- Association for Molecular Pathology 2012 – current
- The Medical Alumni
- American Association for the Advancement of Science
- American Society of Clinical Oncology
- European Society of Medical Oncology
- NATA Assessor 1996 - current
- ANZBCTG member 2008 – current
- ANZBCTG Scientific Advisory Committee 2009 - current
- Queensland Cancer Oncology Group 2003 - current
- Australian Society of Breast Disease 2004 - current
- Australian HER2 Advisory Board 2002 - current
- Member Clinical Council, Princess Alexandra Hospital 2006 – 2011
- Member Critical Incident and Mortality Review Committee PAH 2006 – 2011
- Pathology Queensland representative National Coalition of Public Pathology 2007 – 2012
- CaSS Research Committee 2010 – 2012
- Chair Pathology Queensland Committee for Diagnostic High Throughput Sequencing 2010 – 2011
- Pathology Queensland Molecular Reference Committee 2011 – 2012
- Pathology Queensland Molecular Working Group 2012 - current
- Executive National Coalition of Public Pathology 2010 – 2012
- Pathology Queensland Pathology Executive Management Committee 2005 - 2009
- Pathology Queensland Pathology Service Advisory Committee 2010 - current
- Pathology Queensland Turnaround Time Taskforce 2005 – 2011
- Pathology Queensland Benchmarking Committee 2005 – 2011
- Pathology Terminologies National E-Health Transition Authority 2005 – 2011
- Chair CaSS Pathology Queensland Credentialing Committee 2008 – current
• Pathology Queensland Credentialing Committee 2006 – current
• Mutual Acceptance Model for Multicentre Research Support Group 2006-2008
• Chairman Infection Control Committee Hillcrest Hospital 1998 – 2002
• Chairman Infection Control Committee Mater Hospital 2000 – 2002
• Medical Advisory Board Hillcrest Hospital 1998 – 2002
• Medical Advisory Board Mater Hospital 2000 – 2002
• Medical Advisory Board Pindara Hospital 2003 – 2005
• Infection Control Committee Pindara Hospital 2003 - 2005
• Infection Control Committee John Flynn Hospital 2003-2005
• Secretary Rockhampton and Capricorn Districts Local Medical Association 1994 – 2002